Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the pandemic influenza virus mRNA vaccine developed by its wholly-owned subsidiary Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (hereinafter referred to as “Zhifeilong Koma”) has obtained the State Drug Administration's Drug Clinical Trial Application Acceptance Notice (acceptance number: CXSL2601222). If no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, Zhifeilong Koma may conduct clinical trials according to the submitted plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.